Ghent University Academic Bibliography

Advanced

Cost-benefit of vagus nerve stimulation for refractory epilepsy

Paul Boon UGent, Kristl Vonck UGent, Michel D'Havé, S O'Connor, Tom Vandekerckhove UGent and Jacques De Reuck UGent (1999) ACTA NEUROLOGICA BELGICA. 99(4). p.275-280
abstract
Purpose: Vagus nerve stimulation (VNS) is an established treatment for patients with medically refractory epilepsy who are unsuitable candidates for conventional epilepsy surgery. VNS requires an initial financial investment but apart from our own previous study there are no reports on cost-benefit published to date. The purpose of this paper is to assess prospectively the cost-benefit ratio of VNS in a series of patients with long term follow-up. Methods: Our experience with VNS comprises 25 patients of whom 20 with sufficient follow-up will be further discussed These 20 patients have a mean post-implantation follow-up of 26 months (range : 6-50 months). Mean age was 30 years (range: 12-45 years); mean duration of epilepsy 17 years (range : 5-35 years). We prospectively assessed seizure frequeny: prescribed AEDs, number of hospital admission days and side effects and calculated the epilepsy related direct medical cost and compared this with pre-implantation data. Results: Mean seizure frequency decreased from 14 seizures/month (range. 2-40) to 9 seizules/month (range : 0-30) (p = 0.0003). The mean yearly epilepsy-related direct medical costs per patient dropped from 6,682 USD (range : 829-21,888 USD) to 3,635 USD (range: 684-12,486 USD) (p = 0.0046). The mean number of hospital admission days was reduced from 16 days/year (range : 0-60) to 4 days/year (range : 0-30) (p = 0.0029). Conclusion : VNS is an efficacious and cost-beneficial treatment for refractory partial seizures.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
vagus nerve stimulation (VNS), refractory epilepsy, epilepsy surgery, efficacy, cost-benefit analysis, MEDICALLY INTRACTABLE SEIZURES, SAFETY, TRIAL, CHILDREN
journal title
ACTA NEUROLOGICA BELGICA
Acta Neurol. Belg.
volume
99
issue
4
pages
275 - 280
Web of Science type
Article
Web of Science id
000085277500009
ISSN
0300-9009
language
English
UGent publication?
yes
classification
A1
id
420805
handle
http://hdl.handle.net/1854/LU-420805
date created
2008-06-24 14:00:00
date last changed
2014-01-27 09:36:20
@article{420805,
  abstract     = {Purpose: Vagus nerve stimulation (VNS) is an established treatment for patients with medically refractory epilepsy who are unsuitable candidates for conventional epilepsy surgery. VNS requires an initial financial investment but apart from our own previous study there are no reports on cost-benefit published to date. The purpose of this paper is to assess prospectively the cost-benefit ratio of VNS in a series of patients with long term follow-up. 
Methods: Our experience with VNS comprises 25 patients of whom 20 with sufficient follow-up will be further discussed These 20 patients have a mean post-implantation follow-up of 26 months (range : 6-50 months). Mean age was 30 years (range: 12-45 years); mean duration of epilepsy 17 years (range : 5-35 years). We prospectively assessed seizure frequeny: prescribed AEDs, number of hospital admission days and side effects and calculated the epilepsy related direct medical cost and compared this with pre-implantation data. 
Results: Mean seizure frequency decreased from 14 seizures/month (range. 2-40) to 9 seizules/month (range : 0-30) (p = 0.0003). The mean yearly epilepsy-related direct medical costs per patient dropped from 6,682 USD (range : 829-21,888 USD) to 3,635 USD (range: 684-12,486 USD) (p = 0.0046). The mean number of hospital admission days was reduced from 16 days/year (range : 0-60) to 4 days/year (range : 0-30) (p = 0.0029). 
Conclusion : VNS is an efficacious and cost-beneficial treatment for refractory partial seizures.},
  author       = {Boon, Paul and Vonck, Kristl and D'Hav{\'e}, Michel and O'Connor, S and Vandekerckhove, Tom and De Reuck, Jacques},
  issn         = {0300-9009},
  journal      = {ACTA NEUROLOGICA BELGICA},
  keyword      = {vagus nerve stimulation (VNS),refractory epilepsy,epilepsy surgery,efficacy,cost-benefit analysis,MEDICALLY INTRACTABLE SEIZURES,SAFETY,TRIAL,CHILDREN},
  language     = {eng},
  number       = {4},
  pages        = {275--280},
  title        = {Cost-benefit of vagus nerve stimulation for refractory epilepsy},
  volume       = {99},
  year         = {1999},
}

Chicago
Boon, Paul, Kristl Vonck, Michel D’Havé, S O’Connor, Tom Vandekerckhove, and Jacques De Reuck. 1999. “Cost-benefit of Vagus Nerve Stimulation for Refractory Epilepsy.” Acta Neurologica Belgica 99 (4): 275–280.
APA
Boon, P., Vonck, K., D’Havé, M., O’Connor, S., Vandekerckhove, T., & De Reuck, J. (1999). Cost-benefit of vagus nerve stimulation for refractory epilepsy. ACTA NEUROLOGICA BELGICA, 99(4), 275–280.
Vancouver
1.
Boon P, Vonck K, D’Havé M, O’Connor S, Vandekerckhove T, De Reuck J. Cost-benefit of vagus nerve stimulation for refractory epilepsy. ACTA NEUROLOGICA BELGICA. 1999;99(4):275–80.
MLA
Boon, Paul, Kristl Vonck, Michel D’Havé, et al. “Cost-benefit of Vagus Nerve Stimulation for Refractory Epilepsy.” ACTA NEUROLOGICA BELGICA 99.4 (1999): 275–280. Print.